Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com

Amicus Therapeutics (NASDAQ:FOLD) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday.

Several other equities analysts have also recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. lifted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Guggenheim increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $9.19 on Thursday. Amicus Therapeutics has a 12 month low of $8.78 and a 12 month high of $14.02. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $2.75 billion, a PE ratio of -51.06, a PEG ratio of 1.60 and a beta of 0.61. The stock’s fifty day simple moving average is $9.56 and its 200 day simple moving average is $10.41.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its stake in Amicus Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 1,280 shares during the last quarter. Hazlett Burt & Watson Inc. lifted its stake in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the last quarter. Xponance Inc. grew its holdings in Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 2,249 shares during the period. Finally, Covestor Ltd increased its position in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,312 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.